XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.3
Product revenue and reserves
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Product revenue and reserves Product revenue and reserves
For the three months ended September 30, 2024 and 2023, the Company recorded $10.6 million and $12.3 million, respectively, of product revenue. For the nine months ended September 30, 2024 and 2023, the Company recorded $45.3 million and $21.4 million, respectively, of product revenue. Product revenue by therapy represents:
For the three months ended
September 30,		For the nine months ended
September 30,
2024202320242023
ZYNTEGLO$5,493 $4,851 $35,212 $9,031 
LYFGENIA2,632 — 2,632 — 
SKYSONA2,487 7,430 7,430 12,383 
Total product revenue, net
$10,612 $12,281 $45,274 $21,414 
Six individual customers accounted for 84% of product revenue for the nine months ended September 30, 2024 and two individual customer accounted for 89% of product revenue for the nine months ended September 30, 2023.
The Company considers there to be revenue concentration risks for customers that represent product revenues that exceed 10% of total product revenue. The concentration of the Company’s product revenue within a particular customer may have a material adverse effect on the Company’s revenue and results of operations if sales with the respective customer experience difficulties. All product revenue during the nine months ended September 30, 2024 and 2023 were within the United States.
The following table summarizes an analysis of the change in reserves for gross to net deductions for the periods indicated:
Total
Balance at December 31, 2023
$5,365 
Provision for rebates
8,506 
Payments/credits— 
Balance at September 30, 2024
$13,871